JPWO2022114163A1 - - Google Patents
Info
- Publication number
- JPWO2022114163A1 JPWO2022114163A1 JP2022565479A JP2022565479A JPWO2022114163A1 JP WO2022114163 A1 JPWO2022114163 A1 JP WO2022114163A1 JP 2022565479 A JP2022565479 A JP 2022565479A JP 2022565479 A JP2022565479 A JP 2022565479A JP WO2022114163 A1 JPWO2022114163 A1 JP WO2022114163A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023195187A JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020198044 | 2020-11-30 | ||
| JP2020198044 | 2020-11-30 | ||
| JP2021110912 | 2021-07-02 | ||
| JP2021110912 | 2021-07-02 | ||
| PCT/JP2021/043538 WO2022114163A1 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195187A Division JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022114163A1 true JPWO2022114163A1 (https=) | 2022-06-02 |
| JPWO2022114163A5 JPWO2022114163A5 (https=) | 2023-07-25 |
| JP7393774B2 JP7393774B2 (ja) | 2023-12-07 |
Family
ID=81754499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240002531A1 (https=) |
| EP (1) | EP4253420A4 (https=) |
| JP (2) | JP7393774B2 (https=) |
| KR (1) | KR20230114747A (https=) |
| AU (1) | AU2021387127A1 (https=) |
| CA (1) | CA3199473A1 (https=) |
| IL (1) | IL303154A (https=) |
| MX (1) | MX2023005864A (https=) |
| TW (2) | TW202546008A (https=) |
| WO (1) | WO2022114163A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011121943A (ja) * | 2009-12-07 | 2011-06-23 | Fundacio Privada Inst Catalana De Recerca I Estudis Avancats | Ｈｅｒ２末端切断型変異体ｃｔｆ−６１１に対する抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US11851479B2 (en) * | 2018-06-18 | 2023-12-26 | Dxdiscovery, Inc. | Methods and compositions for pertussis diagnosis |
| US20250222029A1 (en) * | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
-
2021
- 2021-11-29 TW TW114129312A patent/TW202546008A/zh unknown
- 2021-11-29 JP JP2022565479A patent/JP7393774B2/ja active Active
- 2021-11-29 CA CA3199473A patent/CA3199473A1/en active Pending
- 2021-11-29 TW TW110144472A patent/TW202229359A/zh unknown
- 2021-11-29 KR KR1020237017469A patent/KR20230114747A/ko active Pending
- 2021-11-29 AU AU2021387127A patent/AU2021387127A1/en active Pending
- 2021-11-29 EP EP21898135.5A patent/EP4253420A4/en active Pending
- 2021-11-29 IL IL303154A patent/IL303154A/en unknown
- 2021-11-29 MX MX2023005864A patent/MX2023005864A/es unknown
- 2021-11-29 US US18/038,185 patent/US20240002531A1/en active Pending
- 2021-11-29 WO PCT/JP2021/043538 patent/WO2022114163A1/ja not_active Ceased
-
2023
- 2023-08-04 US US18/365,828 patent/US11981747B1/en active Active
- 2023-11-16 JP JP2023195187A patent/JP2024020436A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011121943A (ja) * | 2009-12-07 | 2011-06-23 | Fundacio Privada Inst Catalana De Recerca I Estudis Avancats | Ｈｅｒ２末端切断型変異体ｃｔｆ−６１１に対する抗体 |
Non-Patent Citations (4)
| Title |
|---|
| CRONE, A. S. ET AL., NATURE MEDICINE, vol. Volume 8, Number 5, JPN6021052217, 2002, pages 459 - 465, ISSN: 0005134117 * |
| KANEKO, MIKA ET AL., BIOCHEMISTRY AND BIOPHYSICS REPORTS, vol. Volume 24, 100826, JPN6021052219, 10 October 2020 (2020-10-10), ISSN: 0005134116 * |
| KATO, YUKINARI ET AL., SCIENTIFIC REPORTS, vol. Volume 4, 5924, JPN6021052220, 2014, ISSN: 0005134115 * |
| YAMADA, SHINJI ET AL., MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY, vol. Volume 36, Number 6, JPN6021052221, 2017, pages 287 - 290, ISSN: 0005134114 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3199473A1 (en) | 2022-06-02 |
| WO2022114163A1 (ja) | 2022-06-02 |
| US20240002531A1 (en) | 2024-01-04 |
| EP4253420A4 (en) | 2024-11-06 |
| EP4253420A1 (en) | 2023-10-04 |
| TW202229359A (zh) | 2022-08-01 |
| US11981747B1 (en) | 2024-05-14 |
| MX2023005864A (es) | 2023-06-05 |
| JP7393774B2 (ja) | 2023-12-07 |
| AU2021387127A1 (en) | 2023-06-22 |
| JP2024020436A (ja) | 2024-02-14 |
| KR20230114747A (ko) | 2023-08-01 |
| TW202546008A (zh) | 2025-12-01 |
| IL303154A (en) | 2023-07-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230329 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230406 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230706 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230706 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231003 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231017 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7393774 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |